News

We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...
Danish leader will face a challenging landscape among competitors ...
A Lilly study showed Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with ...
That pundit was HSBC's Rajesh Kumar, who downgraded his recommendation on Novo Nordisk that morning. Image source: . Kumar ...
Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.
Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...
Yesterday, we reported that Novo Nordisk (NYSE: NVO) stock crashed over 20% in premarket trading yesterday. The main culprit is the reduced sales forecast for the company’s flagship obesity drug ...
Indian pharma is hoping to cash in. Generic firms, such as Biocon, are already offering weight-loss drugs, such as cheaper ...
We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. ABC is one of the stocks Jim Cramer recently discussed. Novo Nordisk A/S (NYSE:NVO), the Danish ...
Eli Lilly said on Thursday that its newer diabetes drug Mounjaro outperformed Trulicity, its previously top-selling ...
While Eli Lilly’s diabetes blockbuster was non-inferior to its older incretin therapy Trulicity in a highly anticipated Phase III cardiovascular outcomes trial, analysts had hoped for statistical ...
Pomerantz LLP is investigating claims on behalf of investors of  Novo Nordisk A/S ("Novo Nordisk" or the "Company") (NYSE: NVO).  Such investors are advised to contact Danielle Peyton ...